A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 182 participants.

Also called NCT07555054

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 182 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07555054
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07555054. Randomized; double masking; primary purpose treatment. Start 2026-05-21 (anticipated); primary completion 2027-11-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
Intervention (Drug)
HS-10390
Intervention (Drug)
HS-10390
Intervention (Drug)
HS-10390
Intervention (Drug)
Irbesartan
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07555054
Content hash
2a997b959267fcef006ef4634791bbd14a888a9c6ca3179282e7f9967a658daf